Importance of competing risks in the analysis of anti-epileptic drug failure

Trials

Volumn 8, Issue , 2007, Pages

  Williamson, Paula R ^a   Smith, Catrin Tudur ^a   Sander, Josemir W ^b   Marson, Anthony G ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; TOPIRAMATE;

ANTICONVULSANT THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA COLLECTION METHOD; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; META ANALYSIS; MONOTHERAPY; OUTCOMES RESEARCH; PROBABILITY; RELIABILITY; REMISSION; RETENTION TIME; RISK ASSESSMENT; SEIZURE; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 34247277024     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-8-12     Document Type: Article

References (33)

1. French JA Kanner AM Bautista J Abou-Khalil B Browne T Harden CL Theodore WH Bazil C Stern J Schachter SC Bergen D Hirtz D Montouris GC Nespeca M Gidal B Marks WJ Jr Turk MR Fischer JH Bourgeois B Wilner A Faught RE Jr Sachdeo RC Beydoun A Glauser TA Efficacy and tolerability of the new antiepileptic drugs in treatment of new onset epilepsy: Report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American academy of neurology and the American epilepsy society Neurology 2004 62 1252-60 15111659
2. National Collaborating Centre for Primary Care The epilepsies: The diagnosis and management of the epilepsies in adults and children in primary and secondary care - NICE guideline London: National Institute for Clinical Excellence 2004
3. Commission on antiepileptic drugs Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy Epilepsia 1998 39 799-803 10.1111/j.1528-1157.1998.tb01167.x 9670910
4. Chadwick D Better comparisons of antiepileptic drugs: What measures of efficacy? Pharm World Sci 1997 19 214-216 10.1023/A:1008642623460 9368920
5. Perucca E Evaluation of drug treatment outcome in epilepsy: A clinical perspective Pharm World Sci 1997 19 217-222 10.1023/A:1008698807530 9368921
6. Kalbfleisch JD Prentice RL The statistical analysis of failure time data Wiley, New York 1980
7. Marson AG Williamson PR Hutton JL Clough HE Chadwick DW Carbamazepine versus valproate monotherapy for epilepsy (Cochrane Review) The Cochrane Library Oxford: Update Software 2000 3
8. Taylor S Tudur Smith C Williamson PR Marson AG Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures (Cochrane Review) The Cochrane Library Oxford: Update Software 2001 4
9. Tudur Smith C Marson AG Williamson PR Phenytoin versus valproate monotherapy for partial onset seizures and generalized onset tonic-clonic seizures (Cochrane Review) The Cochrane Library Oxford: Update Software 2001 4
10. Tudur Smith C Marson AG Clough HE Williamson PR Carbamazepine versus phenytoin monotherapy for epilepsy (Cochrane Review) The Cochrane Library Oxford: Update Software 2002 2
11. Tudur Smith C Marson AG Williamson PR Carbamazepine versus phenobarbitone monotherapy for epilepsy (Cochrane Review) The Cochrane Library Oxford: Update Software 2003 1
12. Gamble CL Marson AG Williamson PR Lamotrigine versus carbamazepine monotherapy for epilepsy (Protocol for a Cochrane Review) The Cochrane Library Oxford: Update Software 2004 2
13. Muller MM Marson AG Williamson PR Oxcarbazepine versus phenytoin monotherapy for epilepsy (Protocol for a Cochrane Review) The Cochrane Library Oxford: Update Software 2004 2
14. Tudur Smith C Marson AG Williamson PR Valproate versus phenobarbitone monotherapy for epilepsy [Cochrane protocol] The Cochrane Library Oxford: Update Software 2004 1
15. Lhatoo SD Wong ICK Polizzi G Sander JWAS Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy Epilepsia 2000 41 1592 1596 10.1111/j.1528-1157.2000.tb00165.x 11114218
16. Lhatoo SD Wong ICK Sander JWAS Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy Epilepsia 2000 41 338 341 10.1111/j.1528-1157.2000.tb00165.x 10714407
17. Marson AG Al-Kharusi AM Alwaidh M Appleton R Baker GA Chadwick DW Cramp C Cockerell OC Cooper PN Doughty J Eaton B Gamble C Goulding PJ Howell SJL Hughes A Jackson M Jacoby A Kellett M Lawson GR Leach JP Nicolaides P Roberts R Shackley P Shen J Smith DF Smith PEM Tudur Smith C Vanoli A Williamson PR on behalf of the SANAD Study group Carbamazepine, gabapentin, lamotrigine, oxcarbazepine or topiramate for partial epilepsy: Results from the SANAD trial Lancet
18. Heller AJ Chesterman P Elwes RD Crawford P Chadwick D Johnson AL Reynolds EH Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: A randomised comparative monotherapy trial JNNP 1995 58 44-50
19. de Silva M MacArdle B McGowan M Hughes E Stewart J Reynolds EH Hughes E Neville BGR Johnson AL Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy The Lancet 1996 347 709-13 10.1016/ S0140-6736(96)90074-4
20. Mattson RH Cramer JA Collins JF Smith DB Delgado-Escueta AV Browne TR Williamson PD Treiman DM McNamara JO McCutchen CB Homan RW Crill WE Lubozynski MF Rosenthal NP Mayersdorf A Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures NEJM 1985 313 145-51 3925335
21. Mattson RH Cramer JA Collins JF A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults NEJM 1992 327 76-571 1298221
22. Richens A Davidson DLW Cartlidge NEF Easter DJ A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy JNNP 1994 57 682-687
23. Verity CM Hosking G Easter DJ A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy Dev Med Child Neur 1995 37 97-108
24. Brodie MJ Richens A Yuen AWC Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy The Lancet 1995 345 476-79 10.1016/S0140-6736(95)90581-2
25. Ramsey RE Wilder BJ Murphy JV Holmes GL Uthman B Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic-clonic seizures Epilepsy 1992 5 55-60 10.1016/ S0896-6974(05)80021-0
26. Turnbull DM Howel D Rawlins MD Chadwick DW Which drug for the adult epileptic patient: Phenytoin or valproate? BMJ 1985 290 815-819 1418605 3919805
27. Placencia M Sander JWAS Shorvon SD Roman M Alarcon F Bimos C Cascante S Antiepileptic drug treatment in a community health care setting in northern Ecuador: A prospective 12-month assessment Epilepsy Res 1993 14 237-244 10.1016/0920-1211(93)90048-C 8504794
28. Brodie MJ Overstall PW Giorgi L Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy Epilepsy Res 1999 37 81-87 10.1016/ S0920-1211(99)00039-X 10515178
29. Bill PA Vigonius U Pohlmann H Guerreiro CA Kochen S Saffer D Moore A A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy Epilepsy Res 1997 27 195-204 10.1016/S0920-1211(97)00024-7 9237054
30. Guerreiro MM Vigonius U Pohlmann H de Manreza ML Fejerman N Antoniuk SA Moore A A double-blind controlled trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy Epilepsy Res 1997 27 205-213 10.1016/S0920-1211(97)00025-9 9237055
31. Nieto-Barrera M Brozmanova M Capovilla G Christe W Pedersen B Kane K O'Neill F A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy Epilepsy Res 2001 46 145 155 10.1016/S0920-1211(01)00271-6 11463516
32. Gray RJ Subdistribution analysis of competing risks. Version 2.1-5 2004 http://www.r-project.org
33. Williamson PR Kolamnunnage-Dona R Tudur Smith C The influence of competing risks setting on the choice of hypothesis test for treatment effect Biostatistics 2006 doi: 10.1093/biostatistics/kxl040 17151088